Week 24: First Major Published Endpoint The Phase 2 obesity trial published in the New England Journal of Medicine and indexed on PubMed enrolled 338 adults and used week 24 as the primary body-weight endpoint
These medications are designed to treat obesity as a long-term disease, said Ali
At Vive Ageless Weight Loss, we prioritize personalized treatment plans to meet our patients unique needs and health goals
If retatrutide and other GLP-1 medications also reduce LDL, it makes them powerful dual-action therapies: not just fighting obesity and diabetes, but also reducing heart disease risk
The soup recipes (Recipes 22 to 24) and Greek yogurt bowl (Recipe 31) are particularly useful during the adjustment period
At 24 weeks, reductions in HbA1c levels were dose-related in the retatrutide groups ranging from 0.43 to 2.02%, versus 1.31% in the dulaglutide group and 0.01% in the placebo group [4]